Pay in 4 interest-free payments of $16.25 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Molecular Weight: 467
Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5
Currently CUDC-907 is in phase I clinical trials for patients with solid tumors or lymphoma
5)6)21-27-26-14(3)28(21)22/h7-10
and effective growth suppression by small molecular inhibitors in kidney cancer cells
TZ9 - Rad6 Ubiquitin Inhibitor. CAS# 1002789-86-7 size:10mg solid Molecular Weight: 467TZ9, CAS No. 1002789 86 7, is a selective and cell permeable inhibitor of human E2 ubiquitin conjugating enzyme Rad6B. It binds to the Rad6B catalytic site, inhibits Rad6B induced histone H2A ubiquitination, downregulates intracellular catenin. It can induce G2 M arrest and apoptosis, and inhibit proliferation and migration of metastatic human breast cancer cells (IC50 ~6 M). Product information CAS Number: 1002789 86 7 Molecular Weight: 366. 33
US$ 32.00
US$ 32.00
US$ 8500.00
US$ 169.95
US$ 109.00
US$ 23.75
US$ 109.00
US$ 109.00
US$ 11000.00
US$ 47.00
US$ 122.00
US$ 109.00